New in PTSD Research: Emerging Treatments Are Changing the Field

Research reveals a difficult truth about the treatments we’ve relied on for decades to help people with post-traumatic stress disorder (PTSD): They simply do not work for everyone. Cognitive Processing Therapy (CPT), Prolonged Exposure (PE), and Eye Movement Desensitization and Reprocessing (EMDR), the gold standard first-line treatments, leave between 39% and 72% of military and veteran populations without meaningful symptom relief (Berman et al., 2025; Voigt et al., 2024). For civilians, non-response rates hover around 39% overall (Berman et al., 2025). That leaves a significant portion of trauma survivors still struggling after doing the hard work of therapy.

And then there’s the dropout problem; roughly 16% of adults and 36% of veterans leave PTSD treatment before it’s complete (Berman et al., 2025). The reasons are complex, avoidance is fundamentally a defining feature of PTSD, but the result is the same: people who need help, are not getting it.

Fortunately, the field is moving fast. Researchers, clinicians, and neuroscientists are developing treatments that operate from entirely different angles. Angles that are targeting the nervous system directly, using technology to extend care, and compressing evidence-based therapies into shorter, more tolerable formats. This article explores the most important emerging areas in PTSD treatment that every counselor and therapist should know about.

Part I: Neurobiological Interventions

PTSD is just as much a neurobiological wound, as it is a psychological one. The brain of someone with PTSD looks and functions differently; for example, the amygdala is hyperactivated, the prefrontal cortex is effectively offline, and the hippocampus is structurally altered (Zaretsky et al., 2024). Understanding this is critical because it explains why talk therapy alone sometimes hits a wall. Some emerging interventions bypass the psychological level entirely and go straight to the neurobiology.

Psychedelic-Assisted Therapy

Of all the groundbreaking treatments emerging in the PTSD space, psychedelic-assisted therapy may be generating the most scientific excitement (and the most clinical debate).

Psychedelic-assisted therapy works by using carefully selected compounds to lower the neurobiological barriers that block trauma processing. In Phase 3 clinical trials, MDMA-assisted therapy produced a 22-point greater reduction in CAPS-5 PTSD inventory scores compared to therapy plus placebo (a statistically and clinically significant difference; Mitchell et al., 2023). Response rates at 18 weeks after baseline were 86.5% for the MDMA group compared to 69% for the placebo group (Mitchell et al., 2023).

MDMA appears to work by reducing amygdala reactivity while simultaneously increasing oxytocin and serotonin release, creating a neurochemical window in which trauma memories can be processed without the overwhelming fear response that typically shuts down therapeutic progress (Zaretsky et al., 2024). The FDA granted MDMA breakthrough therapy status, though as of August 2024, it declined initial approval and requested an additional Phase 3 trial (Barnett et al., 2025). The work continues. This is clinically important context: these treatments are not yet available through standard clinical channels in most of the United States.

Psilocybin, the active compound in “magic mushrooms,” is also gaining traction. A Phase 2 trial with participants meeting PTSD criteria found that psilocybin treatment enabled expanded access to self and facilitated non-verbal, somatic processing of traumatic material that participants consistently described as fundamentally distinct from anything they’d experienced in standard first-line treatments (Modlin et al., 2025). An important note: psilocybin remains Schedule I in the United States, though Oregon, Colorado, and Australia have moved toward supervised therapeutic use (National Center for PTSD, 2024a).

The therapy component with this type of treatment is non-negotiable, it's essential. MDMA-assisted therapy requires trained clinician support through preparation, the medicine sessions themselves (typically 6–8 hours), and integration afterward (Mithoefer, 2022). Essentially, the compound doesn’t do the work — it creates the neurological conditions for the therapeutic work to happen more efficiently. That distinction matters clinically and ethically. This is still psychotherapy; it just has a different on-ramp.

Stellate Ganglion Block (SGB)

The Stellate Ganglion Block (SGB) is a minimally invasive procedure in which a local anesthetic is injected around the cervical sympathetic chain, specifically around the stellate ganglion at the C6 vertebral level. This temporarily inhibits sympathetic nervous system activity, which is chronically dysregulated in PTSD (Springer et al., 2024). The procedure takes minutes and is ultrasound-guided for precision and safety. Clinically, SGB has been used in pain medicine for nearly a century; its application to psychiatric conditions is new territory.

Across the full body of published literature, between 70% and 83% of patients who receive SGB show clinically significant positive outcomes (Springer et al., 2024). A 2023 study found SGB reduced anxiety symptoms, as measured by the GAD-7 inventory, by approximately half (Lynch et al., 2023, as cited in Springer et al., 2024). The proposed mechanism involves SGB’s suppression of Nerve Growth Factor (NGF) and modulation of the hypothalamic-pituitary-adrenal (HPA) axis, fundamentally interrupting the neurobiological stress cascade that sustains PTSD symptoms over time (Yang et al., 2025).

An important lesson here for clinicians: SGB is not a standalone cure. The clinical literature increasingly supports combining SGB with trauma-focused talk therapy to optimize outcomes; the block appears to create a window of neurobiological openness that can enhance the impact of concurrent psychotherapy (Springer et al., 2024; Peterson et al., 2022). Think of it as partially clearing the neurological noise so the therapeutic signal can get through more effectively.

Neurofeedback and Brainwave Regulation

The brains of people with PTSD oscillate differently. For example, increased beta wave activity is linked to hyperarousal and sleep disruption and deficits in alpha wave production correlate with sensory disinhibition and chronic hypervigilance. And, the default mode network and salience network, key functional brain systems, show measurable dysregulation in PTSD (Askovic et al., 2023). Neurofeedback directly targets these patterns.

Electroencephalographic Neurofeedback (EEG-NFB) uses real-time EEG data to present patients with moment-by-moment feedback, typically a visual or auditory cue, about their brainwave activity. Through operant conditioning, patients learn to shift their own neural patterns over time (Askovic et al., 2023). In simpler terms: the brain is shown what it’s doing and gradually taught to do something healthier. No medication, no direct tissue intervention, just the brain learning to regulate itself. This treatment has particular appeal for clients who have strong reservations about pharmacological treatment.

A recent research study has shown a large effect size in favor of neurofeedback for PTSD symptom reduction, with moderate-to-high certainty evidence (Voigt et al., 2024). Improvements in brainwave synchrony, network connectivity normalization, and restoration of the brain’s excitatory/inhibitory balance were documented across multiple studies (Askovic et al., 2023). These neurophysiological changes correspond to improvements in clients’ ability to self-regulate emotional responses to trauma-related triggers.

A particularly promising development is Amygdala-EEG Fingerprint Neurofeedback (Amyg-EFP-NF), which fuses simultaneous EEG and fMRI recordings to create individualized amygdala biomarkers that guide training. The FDA cleared this approach in early 2023 for use as an adjunct to evidence-based PTSD treatments (Voigt et al., 2024). A combined analysis of three clinical trials found Amyg-EFP-NF produced significant reductions across all PTSD symptom clusters immediately post-treatment, with improvements maintained at three-month follow-up and large effect sizes across all clusters (Fruchter et al., 2025).

From a cost perspective, an area that matters enormously for treatment accessibility, neurofeedback as an adjunct to standard therapy was not only more effective but also less expensive over 1–3 years than psychotherapy and pharmacotherapy alone (Voigt et al., 2025). That’s a rare trifecta in healthcare: better outcomes, better tolerability, and lower cost.

Part II: Technology-Assisted Therapies

One of the most pressing challenges in PTSD treatment isn’t clinical, it’s logistical. Even when effective treatments exist, access remains a barrier. Geographic isolation, provider shortages, stigma, scheduling constraints, and cost all create distance between trauma survivors and quality care. Technology is beginning to close that gap, and in some cases it’s transforming the therapeutic experience itself in meaningful ways.

Virtual Reality (VR) Therapy

Exposure therapy is one of the most effective treatments for PTSD, and also one of the most avoided, both by clients and, sometimes by therapists. The therapeutic demand to approach rather than avoid trauma-related stimuli is exactly what makes it effective and exactly what makes it hard. Virtual Reality Exposure Therapy (VRET) offers a meaningful solution to this challenge.

VR creates multi-sensory, immersive, trauma-relevant environments (visual, auditory, and in some systems olfactory and haptic) that can be precisely calibrated to an individual’s trauma and adjusted in real time by the clinician (Heo & Park, 2022). Compared to imaginal exposure, VR provides greater ecological validity and emotional engagement, which may enhance the inhibitory learning and fear extinction processes that drive exposure therapy’s effectiveness. And critically, the controlled nature of the virtual environment means the clinician can pause, adjust, and calibrate the experience in ways that simply aren’t possible in real-world exposure.

Traditional exposure therapy dropout rates are substantial and well-documented but VRET consistently shows lower dropout rates than conventional exposure therapy (Heo & Park, 2022). VRET is a treatment that’s slightly less powerful, but actually gets completed; which beats a superior treatment the client abandons after session two. In most cases, completion is the variable we need to optimize for first with exposure therapy approaches.

Mobile Apps and Wearables

Most of us see our clients once a week, if we’re lucky. But PTSD doesn’t observe a weekly schedule. Triggers, nightmares, hyperarousal episodes, and dissociative intrusions happen at 2 a.m. on a Tuesday, in a grocery store, sitting in traffic. Mobile apps and wearable technology represent a genuine attempt to extend the therapeutic reach into those in-between spaces where clients are on their own.

The overall landscape of mental health apps is large and, in many cases, evidence-light. That said, apps specifically designed to augment (not replace!) PTSD-focused therapy show considerable promise. A 2023-2024 development and pilot study by Black Dog Institute, created a smartphone app aligned with trauma-focused CBT principles specifically for frontline workers with PTSD (Deady et al., 2024). The app, called Support Base, enabled homework completion, reinforced key therapeutic concepts, and provided between-session crisis support, which addresses one of the most significant practical barriers to PTSD treatment progress (Deady et al., 2024). Further, the National Center for PTSD’s PTSD Coach App and the Virtual Hope Box represent two VA/DoD-developed tools with documented evidence among veteran populations (Torous et al., 2022).

Wearable devices offer an additional layer of physiological monitoring that can meaningfully inform treatment. Wearables can track sleep quality, heart rate variability (a reliable marker of autonomic nervous system dysregulation common in PTSD), physical activity, and physiological stress indicators in real time. This is data that can be reviewed collaboratively in session and integrated into treatment planning. The Apollo Neuro is a wearable that delivers precisely calibrated vibroacoustic stimulation - silent, low-frequency vibrations worn on the wrist, ankle, or clipped to clothing- that activate the parasympathetic nervous system by mimicking the oscillation pattern between the heart and lungs during deep breathing (Apollo Neuroscience, 2022). While the research is still underway for the Apollo Neuro, results are promising. An important clinical consideration: digital tools work best when they’re integrated into a structured treatment plan and reviewed collaboratively with the client. The technology alone won’t improve outcomes, the clinician’s intentional use of it is what creates value. Assigning an app without follow-up is likely less useful than spending five minutes each session reviewing what the app captured.

Part III: Accelerated Trauma-Focused Psychotherapies

Evidence-based psychotherapies like PE and CPT work; the research on this is robust and consistent. But the delivery model, once a week for 12-16 weeks, creates real problems for clients. Dropout rates are high, progress can stall between widely spaced sessions as avoidance takes hold again, and for many populations (e.g., active-duty military, first responders, clients with logistical constraints, clients who live in rural areas) a months-long weekly therapy commitment is simply not feasible. So, researchers started asking whether compressing evidence-based trauma therapies into shorter, more intensive formats would maintain or potentially improve outcomes. In most cases, the results are encouraging.

Intensive Outpatient Programs (IOPs)

Intensive Outpatient Programs (IOPs) for PTSD deliver trauma-focused therapies in condensed, multi-session daily formats, typically 2-3 weeks rather than several months. A landmark 2023 randomized clinical trial compared massed Prolonged Exposure (15 sessions over 3 weeks) to a full IOP-PE format (15 full-day treatment sessions over 3 weeks with eight additional treatment augmentations) in active-duty service members with combat-related PTSD. Both formats produced substantial PTSD symptom reduction, and the IOP demonstrated meaningfully higher retention rates, directly addressing the dropout problem that plagues standard weekly delivery (National Center for PTSD, 2024b).

Fortunately, it appears that compression doesn’t appear to trade durability for speed; the treatment gains hold over time. The theoretical underpinning for massed delivery has support from fear extinction research: massed extinction trials may create more durable inhibitory learning compared to widely spaced exposures, and higher session frequency was found to be associated with significantly greater PTSD symptom reduction even after controlling for total session number (National Center for PTSD, 2024b).

Massed Cognitive Processing Therapy

CPT, which targets stuck-point beliefs and distorted cognitions related to trauma, has also been adapted into accelerated intensive formats. Intensive CPT delivered over 1-2 weeks has produced treatment outcomes comparable to standard weekly CPT in multiple studies, with the important added advantage of substantially reduced dropout (Weinstein et al., 2023). More research comparing massed to standard CPT delivery is underway (National Center for PTSD, 2024b).

Intensive Online Trauma Treatment

In an important development for access and reach, intensive trauma treatment has also been adapted for fully online delivery. A 2024 case study transformed a six-day in-person intensive program, combining Prolonged Exposure, EMDR 2.0, exercise, and psychoeducation, into a fully online format and achieved substantial symptom reduction in a client with severe, chronic, treatment-resistant PTSD (Matthijssen & Menses, 2024). The online format didn’t appear to significantly dilute the potency of the intensive approach.

As telehealth infrastructure continues to improve and normalize, this creates possibilities for reaching clients who previously had no access to intensive trauma programs due to geography, disability, or caretaking responsibilities. The combination of intensive delivery and online format essentially removes two of the most common barriers to PTSD treatment simultaneously.

Where does this leave us?

None of these treatments are magic, and none of them replace the fundamental therapeutic relationship or the hard, courageous work of trauma processing. These treatments represent a genuinely exciting expansion of the clinical toolkit: interventions that can help the clients who have tried everything else, that can make the delivery of proven treatments more tolerable and accessible, and that address PTSD at a neurobiological level that talk therapy alone cannot always reach.

The main points to take away from this article are these: 1. the brain can change, even in chronic, treatment-resistant PTSD; 2. neurobiological interventions like SGB, psychedelic-assisted therapy, and neurofeedback can create the conditions for that change; 3. technology can extend our reach and enhance between-session support; and, 4. the way we deliver proven therapies matters as much as the therapies themselves. In most cases, the most effective path forward will involve combining approaches rather than choosing just one.

The field is moving toward a more personalized, multimodal approach to PTSD, one that assesses each client’s neurobiology, history, logistical realities, and treatment preferences, and then builds a tailored pathway that may combine conventional psychotherapy with one or more of the emerging approaches described here. Overall, this is the direction trauma treatment is headed, and staying current on the evidence is part of the ethical commitment to the clients who trust us with their worst experiences.